Answers are grounded in this paper and cite their sources.
This focus issue highlights recent advances in vascular biology and medicine, including stroke reperfusion, single-cell biology in atherosclerosis, VTE risk prediction, and novel therapeutic targets for aortic dissection and pulmonary hypertension.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Focus Issue on vascular biology and medicine contains a State of the Art Review article entilted ‘Acute ischaemic stroke: recent advances in reperfusion treatment’ by Petr Widimsky from the Charles University and University Hospital Kralovske Vinohrady in Prague, Czech Republic, and colleagues.1 Stroke is a major clinical challenge.2–8 The authors note that during the last 5–7 years, tremendous progress was achieved in the reperfusion treatment of acute ischaemic stroke during its first few hours from symptom onset. This review summarizes the latest evidence from randomized clinical trials and prospective registries, with a focus on endovascular treatment using stent retrievers, aspiration catheters, thrombolytics, and (in selected patients) carotid stenting. Novel approaches in pre-hospital (mobile interventional stroke teams) and early hospital (direct transfer to angiography) management are described, and future perspectives (‘all-in-one’ laboratories with angiography and computed tomography integrated) are discussed. There is a reasonable chance for patients with moderate to severe acute ischaemic stroke to survive without permanent sequelae when the large-vessel occlusion is removed by means of a modern pharmaco-mechanical approach. Catheter thrombectomy is now the golden standard of acute stroke treatment. The role of cardiologists in stroke is expanding from diagnostic help (to reveal the cause of stroke) to acute therapy in those regions where such up-to-date Class Ia treatment is not yet available. In a State of the Art Review article entitled ‘Translational opportunities of single-cell biology in atherosclerosis’, Menno de Winther from the University of Amsterdam in the Netherlands, and colleagues note that the advent of single-cell biology opens a new chapter for understanding human biological processes and for diagnosing, monitoring, and treating disease.9 This revolution has now reached the field of cardiovascular disease (CVD).10 New technologies to interrogate CVD samples at single-cell resolution are allowing the identification of novel cell communities that are important in shaping disease development and directing towards new therapeutic strategies. These approaches have begun to revolutionize atherosclerosis pathology and redraw our understanding of disease development. This review discusses the state-of-the-art of single-cell analysis of atherosclerotic plaques, with a particular focus on human lesions, and presents the current resolution of cellular subpopulations and their heterogeneity and plasticity in relation to clinically relevant features. Opportunities and pitfalls of current technologies as well as the clinical impact of single-cell technologies in CVD patient care are highlighted, advocating for multidisciplinary and international collaborative efforts to join the cellular dots of CVD. BMI, body mass index; DOAC, direct oral anticoagulant; DVT, deep venous thrombosis; Hb, haemoglobin; SBP, systolic blood pressure; VKA, vitamin K antagonist; VTE, venous thrombo-embolism.12 Deciding to stop or continue anticoagulation for venous thrombo-embolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous.11 In a Clinical Research article entitled ‘Recurrent venous thrombo-embolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score’, Maria de Winter from the University Medical Center Utrecht in the Netherlands, and colleagues aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment, which can be used to estimate individual absolute benefits and harms of extended anticoagulation.12 Competing risk-adjusted models were derived to predict recurrent VTE and clinically relevant bleeding (non-major and major) using 14 readily available patient characteristics. The models were derived from combined individual patient data from the Bleeding Risk Study, Hokusai-VTE, PREFER-VTE, RE-MEDY, and RE-SONATE. External validity was assessed in the Danish VTE cohort, EINSTEIN-CHOICE, GARFIELD-VTE, MEGA, and Tromsø studies. Absolute treatment effects were estimated by combining the models with hazard ratios from trials and meta-analyses. External validation in different settings showed agreement between predicted and observed risks up to 5 years, with C-statistics ranging from 0.48 to 0.71 (recurrence) and from 0.61 to 0.68 (bleeding) (Figure 1). The authors conclude that the VTE-PREDICT risk score can be applied to estimate risk and benefits of extended anticoagulant treatment for individual patients with VTE and to support shared decision-making. The contribution is accompanied by an Editorial by Gregory Piazza from Harvard Medical School in Boston, MA, USA.13 The authors note that the VTE-PREDICT Study Group should be commended not only for providing a tool to facilitate shared decision-making around duration of anticoagulation after VTE but also for the method by which this risk score was derived and tested. By using a rich collection of clinical trial and observational cohort studies, the investigators have incorporated an inclusive and rigorous group of datasets. With the VTE-PREDICT risk score, clinicians can now be better prepared to enter a more balanced shared decision-making discussion that prioritizes patient safety and preferences. We now have a tool that enables us to look to a brighter future—one in which we can more precisely individualize long-term prevention pathways for our patients with VTE. The disruption of endothelial tight junctions (TJs) emerged as an early pathological change in the progression of thoracic aortic aneurysm and dissection (TAAD). Evaluating the function of the endothelial TJs by magnetic resonance imaging (MRI) could predict the occurrence of TAAD, and sealing TJs prevented the incidence of TAAD. Inflammatory cells and water transported across the impaired endothelial TJs caused vascular inflammation and oedema, and eventually caused TAAD.17 Mechanisms responsible for aortic aneurysm and dissection are still largely unknown.14–16 In a Translational Research article entitled ‘Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection’, Xueyuan Yang from the Peking University in China, and colleagues point out that whether changes in endothelial tight junctions (TJs) lead to the formation of thoracic aortic aneurysm and dissection (TAAD) and serve as an early indicator and therapeutic target remains elusive.17 Single-cell RNA sequencing analysis showed aberrant endothelial TJ expression in the thoracic aortas of patients with TAAD. In a β-aminopropionitrile (BAPN)-induced TAAD mouse model, endothelial TJ function was disrupted in the thoracic aortas at an early stage (5 and 10 days) as observed by a vascular permeability assay, while the intercellular distribution of crucial TJ components was significantly decreased by en face staining. For the non-invasive detection of endothelial TJ function, two dextrans of molecular weights 4 and 70 kDa were conjugated with the magnetic resonance imaging (MRI) contrast agent Gd-DOTA (gadolinium-tetraazacyclododecanetetraacetic acid) to synthesize fluorescein isothiocyanate (FITC)–dextran–DOTA-Gd and rhodamine B–dextran–DOTA-Gd. MRI images showed that both probes accumulated in the thoracic aortas of the BAPN-fed mice. In particular, the mice with increased accumulated signals from 5 to 10 days developed TAAD at 14 days, whereas the mice with similar signals between the two time points did not. Furthermore, the protease-activated receptor 2 inhibitor AT-1001, which seals TJs, alleviated the BAPN-induced impairment of endothelial TJ function and expression and subsequently reduced TAAD incidence. Notably, endothelial-targeted ZO-1 conditional knockout increased TAAD incidence. Mechanistically, vascular inflammation and oedema were observed in the thoracic aortas of the BAPN-fed mice, whereas these phenomena were attenuated by AT-1001 (Figure 2). The authors conclude that the disruption of endothelial TJ function is an early event prior to TAAD formation, herein serving as a potential indicator and a promising target for TAAD. This manuscript is accompanied by an Editorial by Aline Verstraeten, Bart Loeys, and Ivanna Fedoryshchenko from the Antwerp University Hospital in Belgium.18 The authors conclude that it will be important to determine whether this observation is specific to the BAPN dissection model or can be extrapolated to other TAA(D) models. Mechanisms responsible for pulmonary hypertension (PH) are complex and intensely investigated.19–21 Proliferation of vascular smooth muscle cells (VSMCs) is a hallmark of PH. In another Translational Research article entitled ‘Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models’, Qian Ma from Augusta University in Augusta, GA, USA, and colleagues note that proliferative cells utilize purine bases from the de novo purine synthesis (DNPS) pathways for nucleotide synthesis; however, it is unclear whether DNPS plays a critical role in VSMC proliferation during development of PH.22 The last two steps of DNPS are catalysed by the enzyme 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC). This study investigated whether ATIC-driven DNPS affects the proliferation of pulmonary artery smooth muscle cells (PASMCs) and the development of PH. ATIC expression was assessed in platelet-derived growth factor-treated PASMCs and in the lungs of PH rodents and patients with pulmonary arterial hypertension (PAH). Mice with global and VSMC-specific knockout of Atic were utilized to investigate the role of ATIC in murine PH models. ATIC-mediated DNPS at the mRNA, protein, and enzymatic activity levels was increased in platelet-derived growth factor-treated PASMCs or PASMCs from PH rodents and patients with PAH. In cultured PASMCs, ATIC knockdown decreased DNPS and nucleic acid DNA/RNA synthesis, and reduced cell proliferation. Global or VSMC-specific knockout of Atic attenuated vascular remodelling and inhibited the development and progression of both hypoxia- and lung interleukin-6/hypoxia-induced PH in mice. Ma and colleagues conclude that targeting ATIC-mediated DNPS compromises the availability of purine nucleotides for incorporation into DNA/RNA, reducing PASMC proliferation and pulmonary vascular remodelling and ameliorating the development and progression of PH. The contribution is accompanied by an Editorial by Gayathri Viswanathan and Sudarshan Rajagopal from Duke University School of Medicine in Durham, NC, USA.23 The authors conclude that this work establishes ATIC and the DNPS pathway as a potential drug target in PAH. Notably, an ATIC inhibitor has been described, which functions by preventing enzyme homodimerization, required for its activity. This inhibitor has been used in cancer models and as a potential radiosensitizing agent, but it also promotes AMP kinase activation, with contrasting effects on the development of PH in different studies. There is also a larger question as to whether purine nucleotide depletion would be safe as a long-term strategy: purine nucleotide depletion has been shown to promote cell migration and epithelial–mesenchymal transition, and, in cancer models, metastatic colonization. Future studies are required to test whether targeting ATIC in PAH will be a viable strategy. The editors hope that this issue of the European Heart Journal will be of interest to its readers. Dr. Crea reports speaker fees from Abbott, Amgen, Astra Zeneca, BMS, Chiesi, Daiichi Sankyo, Menarini outside the submitted work. With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2023) conducted an editorial in Vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: